• People born in the United States in 1980 or later
  
• People who have never received a diagnosis or verificiation of history of varicella infection or hepres zoster infection by a health care provider
• People who do not have laboratory evidence of immunity or disease
• People who have close contact with other people who are at high risk for chickenpox (such as health care workers and those who live with people who have a weakened immune system)
• People in settings where chickenpox can spread easily (such as teachers, childcare workers, and college students)
• International travelers

• Pregnant women
• People with a weakened immune system
• People with HIV infection and a CD4 percentage <15% or a CD4 count under 200

• Anyone who wants protection against hepatitis A virus infection
• People with chronic liver disease (such as alcoholic liver disease or cirrhosis)
• People who use drugs
• Men who have sex with men
• Persons experiencing homelessness
• People who travel outside of the United States to areas where hepatitis A is common*
• People who work with hepatitis A virus in a laboratory
• People who have close contact with an international adoptee from an area where hepatitis A is common*
• People who work in settings that have direct contact with others who have hepatitis A

• All adults 19 through 59 years of age
• People 60 years or older with known risk factors for hepatitis B virus infection
• Anyone who wants protection against hepatitis B virus infection
• People who are at risk by blood or mucus exposure (for example, health care workers and people who use injection drugs)
• People who are at risk by sexual contact (for example, sexually active persons who are not in monogamous relationships)
• Men who have sex with men
• People living with someone who has active hepatitis B infection
• People with end-stage kidney disease (or on dialysis), diabetes, chronic liver disease (such as alcoholic liver disease or cirrhosis) or hepatitis C infection, or HIV infection
• Staff and clients in sexually transmitted disease, HIV, drug abuse, hemodialysis, developmental disabilities, or correctional facilities
• People who travel outside of the United States to areas where hepatitis B is common*

• People with a missing or damaged spleen or sickle cell disease
• People who received hematopoietic stem cell transplant (such as a bone marrow transplant)

• Anyone who has not completed the HPV vaccination series through age 26 years

• If you have never received a complete polio vaccination series (i.e., at least 3 doses).
• If you have completed the polio vaccination series (i.e., at least 3 doses), you may receive one lifetime IPV booster dose.

• People 6 months of age or older who do not have contraindications
• People who are 65 years of age and older should receive a high-dose influenza vaccine. If not available, then any other age appropriate influenza vaccine should be used.

• People who have had a severe reaction to a flu vaccine

• People with a missing or damaged spleen, sickle cell disease, or complement deficiencies
• People who work with meningococcal bacteria in the laboratory

• People with HIV infection
• Military recruits
• First-year college students who live in residential housing if they did not receive MenACWY at age 16 years or older
• People who travel to countries where meningococcal disease is common*

• Some healthy young adults 16 through 23 years of age after discussion with their health care provider

• People born in 1957 or later
• Women who are not pregnant, but could become pregnant; rubella could cause miscarriage or serious birth defects
• International travelers, close contacts of people with weakened immune systems, and college students
• Health care workers

• Pregnant women
• People with a weakened immune system
• People with HIV infection and a CD4 count under 200

• A new diagnosis of at least 1 sexually transmitted disease
• More than 1 sex partner
• Sex at a commercial sex venue
• Sex in association with a large public event in a geographic area where Mpox transmission is occurring


• Persons who are sexual partners of the persons described above
• Persons who anticipate experiencing any of the situations described above

• Adults aged 60 years and older may receive a single dose of RSV vaccine using shared clinical decision-making.
• Pregnant people eligible for maternal RSV vaccine during weeks 32 through 36 of pregnancy, administered immediately before or during RSV season. Alternatively, an infant can be immunized with an RSV monoclonal antibody to prevent respiratory syncytial virus lower respiratory tract infection in infants

• People 65 years of age and older who have not received a pneumococcal conjugate vaccine or whose previous vaccination history is unknown
• People 19 -64 years of age with certain underlying medical conditions or other risk factors*

* Underlying medical conditions or other risk factors include alcoholism, chronic heart/liver/lung disease, chronic renal failure, cigarette smoking, cochlear implant, congenital or acquired asplenia, CSF leak, diabetes mellitus, generalized malignancy, HIV, Hodgkin disease, immunodeficiency, iatrogenic immunosuppression, leukemia, lymphoma, multiple myeloma, nephrotic syndrome, solid organ transplants, or sickle cell disease or other hemoglobinopathies.

• People with certain immunocompromising conditions,** cochlear implants and cerebrospinal fluid leaks.
• People with cerebrospinal fluid leak or cochlear implant

**Immunocompromising conditions include chronic renal failure, nephrotic syndrome, immunodeficiency, iatrogenic immunosuppression, generalized malignancy, human immunodeficiency virus, Hodgkin disease, leukemia, lymphoma, multiple myeloma, solid organ transplants, congenital or acquired asplenia, sickle cell disease, or other hemoglobinopathies.

• People who previously did not receive a dose of Tdap (Tdap is routinely given at age 11-12 years).
• People who did not receive primary vaccination series for tetanus, diphtheria, and pertussis.
• People who have completed their childhood tetanus-diphtheria-pertussis vaccination series that did not include a dose of Tdap (Tdap is routinely given at age 11-12 years)
• Pregnant women (a dose of Tdap should be given during each pregnancy)
• People who have close contact with infants younger than 12 months
• Health care workers
• People who sustained a dirty wound and have not received tetanus toxoid containing vaccine in the last 5 years.

• People who have not received Td or Tdap vaccine in the last 10 years
• People who sustained a dirty wound and have not received tetanus toxoid containing vaccine in the last 5 years.
• See related recommendations for tetanus, diphtheria, and pertussis vaccine (Tdap). People need a booster dose of either Td or Tdap every 10 years.

• Adults 50 years of age and older
• Adults 19-49 years of age with immunocompromising conditions, including HIV
• Adults who already received ZVL(Zostavax) should get RZV (Shingrix)

• Pregnant women should consider delaying RZV until after pregnancy